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A target-protection mechanism 
of antibiotic resistance at atomic 
resolution: insights into FusB-type 
fusidic acid resistance
Jennifer H. Tomlinson1,2, Gary S. Thompson1,2, Arnout P. Kalverda1,2, Anastasia Zhuravleva1,2 
& Alex J. O’Neill1,2
Antibiotic resistance in clinically important bacteria can be mediated by proteins that physically 
associate with the drug target and act to protect it from the inhibitory effects of an antibiotic. We 
present here the first detailed structural characterization of such a target protection mechanism 
mediated through a protein-protein interaction, revealing the architecture of the complex formed 
between the FusB fusidic acid resistance protein and the drug target (EF-G) it acts to protect. Binding 
of FusB to EF-G induces conformational and dynamic changes in the latter, shedding light on the 
molecular mechanism of fusidic acid resistance.
Antibiotic resistance is an evolving crisis that threatens to undermine our ability to treat bacterial infection1. To 
effectively tackle this issue, a comprehensive understanding of bacterial resistance to antibiotics will be crucial. In 
particular, it will be important to achieve a detailed knowledge of the molecular mechanisms involved, not least 
because such information could potentially inform strategies to inhibit these mechanisms and thereby rejuvenate 
the clinical efficacy of antibacterial drugs whose activity has become compromised by resistance.
Whilst there has been extensive study into the mechanisms of antibiotic resistance, and a broad understanding 
now exists, some notable gaps in our knowledge remain. One of these concerns the phenomenon of target protec-
tion by protein-protein interaction, wherein an antibiotic resistance protein directly binds the drug target protein 
and acts to protect it from the inhibitory effects of an antibiotic. To date, only two examples of such a resistance 
mechanism have been identified to mediate clinically significant antibiotic resistance; FusB-type resistance to 
fusidic acid (FA), and Qnr-mediated resistance to fluoroquinolones2,3. In neither case is there an understanding 
at the molecular level of the structural basis for the protein-protein interaction or of the mechanism by which the 
interaction gives rise to resistance. Here we describe a series of studies to gain insight into both of these aspects 
for the target protection mechanism of FA resistance mediated by FusB-type proteins.
FA is widely used as a topical agent to treat staphylococcal skin infection, and is also one of the few remaining 
oral antibiotics effective against methicillin-resistant Staphylococcus aureus (MRSA)4,5. FA acts by interfering 
with correct functioning of elongation factor G (EF-G)6,7, the protein responsible for catalyzing translocation 
of peptidyl-tRNA from the A site to the P site of the ribosome during protein synthesis8. Once transloca-
tion has occurred, EF-G ordinarily dissociates from the ribosome, vacating the A site for the next incoming 
aminoacyl-tRNA species. In the presence of FA, the drug binds to EF-G on the ribosome and inhibits its release, 
thereby preventing further protein synthesis and leading to growth arrest6,7.
Recent years have seen a dramatic increase in resistance to FA in clinical strains of S. aureus and other staphy-
lococci9. In most FA-resistant strains, resistance is the result of horizontal acquisition of determinants that encode 
FusB-type proteins9–13. Members of the FusB family, the best studied of which is FusB itself, are small (~25 kDa) 
proteins that bind EF-G with a 1:1 stoichiometry14 and protect it from the inhibitory effect of FA. X-ray crystal-
lographic studies have determined the 3D structures of two representatives of the FusB family14,15, revealing a 
two-domain protein with an unusual zinc-binding fold in the C-terminal domain. Through direct interaction 
with EF-G, FusB promotes disassembly of the FA-stalled post-translocation complex, thereby rescuing protein 
synthesis14,16. FusB has also been shown to increase turnover of EF-G on the ribosome in the absence of FA, 
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implying that it acts to accelerate the conformational rearrangement within EF-G necessary for dissociation from 
the ribosome14. The ability of FusB to drive EF-G release explains why it mediates resistance to FA; this effect will 
directly counter that of FA, which is acting to prevent dissociation of EF-G from the ribosome. How FusB might 
achieve this effect remains an outstanding question.
To enable an understanding of the mechanism of FusB-mediated target protection, an appreciation of the 
molecular details of the interaction occurring between the resistance protein and the drug target will be required. 
Although individual structures of S. aureus EF-G17–22 and FusB-type proteins14,15 have been determined (Fig. 1), 
the structure of the two proteins in complex has not, and attempts to produce crystals of the FusB•EF-G complex 
for structural determination by X-ray diffraction have to date not proven successful (unpublished data). As a 
consequence, only limited information exists regarding the architecture of the complex. NMR minimal chemical 
shift perturbations (CSPs) and mutagenesis mapping have established that regions within the C-terminal domain 
of FusB represent the primary site of interaction with EF-G14,23. The corresponding site of interaction on EF-G is 
less well defined, although FusB has been shown to bind with comparable affinity to an EF-G fragment (EF-GC3) 
lacking the N-terminal domains I and II, implying that the binding site resides within domains III-V14.
Here, we employed solution NMR to elaborate a structural model of the FusB•EF-G complex. In addition 
to delineating the architecture of the resistance protein in complex with the drug target, this approach revealed 
conformational and dynamic changes occurring in EF-G upon complexation that provide an explanation for the 
action of FusB on EF-G, and in turn, the mechanism of FusB-mediated resistance to FA.
Results
Establishing a model system for NMR characterization of the FusB•EF-G complex. The ability 
to effectively study protein complexes by NMR is strongly influenced by molecular size, with smaller systems 
achieving greater accuracy and enabling the use of a wider range of methodological approaches. In view of this, 
and of the equivalent FusB-binding properties of EF-G (77 kDa) and the truncated version of the protein, EF-GC3 
(35 kDa)14, we chose the latter for studying the FusB•EF-G complex by NMR. To ensure that truncation of EF-G 
did not perturb the structure of the protein, we compared 15N-TROSY-HSQC spectra of the truncated and full-
length proteins in both apo and FusB-bound states. Spectra from EF-G and EF-GC3 overlaid well (Supplementary 
Fig. 1), revealing no significant chemical shift differences apart from isolated effects along the interfaces with 
domains I and II (domains missing from the truncated version). Amide residual dipolar coupling (RDC) meas-
urements, which provide a good measure of the local structure for each residue and allow the determination of 
the relative orientation of domains and secondary structure elements, established that EF-GC3 fits well to the 
crystal structure of S. aureus EF-G (PDB ID 2XEX)17 (Supplementary Fig. 2) (Q factor of 0.39), indicating that 
no interdomain changes occur upon truncation of the protein. RDCs measured in FusB also confirmed a good 
fit between the crystal structure15 and solution structure of this protein (Supplementary Fig. 2) in the apo state 
(Q factor of 0.41). Thus, the solution structures of apo FusB and apo EF-GC3 do not differ substantially from the 
published crystal structures, and EF-GC3 represents a suitable surrogate for the full-length protein in interaction 
studies with FusB.
Towards determination of a large, multidomain complex structure using NMR. Structural deter-
mination of large protein complexes using NMR spectroscopy remains a considerable challenge. This reflects 
the fact that the number and types of structural restraints that can be determined are limited, and consequently 
models must be based on sparse data sets. Although a variety of approaches have been utilized to obtain such 
structural data using different types of sparse data sets24–27, most rely on expensive and time-consuming selective 
labelling of methyl groups, and no uniformly successful approach has yet been detailed28. Here, we combined 
several well-established techniques24,26,29–33 to drive docking calculations in a streamlined protocol that did not 
Figure 1. Structures of S. aureus EF-G and FusB-type proteins. (a) S. aureus EF-G (PDB ID 2XEX), 
annotated by domain, and shown with fusidic acid (magenta sticks) modelled in the binding site through 
alignment with the structure of ribosome-bound, FA-bound EF-G from Thermus thermophilus (PDB ID 2WRI). 
(b) FusB-type proteins, FusB (PDB ID 4ADN, colored blue and red) and FusC (PDB ID 2YB5, colored green 
and yellow) annotated by domain. The coordinated zinc ion in the C-terminal domain is shown as a magenta 
sphere.
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require selective methyl labelling or nuclear Overhauser effect (NOE) data. This three step approach, detailed 
below, allowed us to produce a structural model of the 60 kDa FusB•EF-GC3 complex and identify structural 
changes occurring in the binding partners at sub-domain level upon complex formation.
Step 1: Defining the structure of the individual protein domains using RDC and solvent PRE (paramagnetic relaxa-
tion enhancement) measurements. To assess structural changes within individual domains upon complexation, 
amide RDCs measured in the complex within expected secondary structure elements were fitted to the crystal 
structures of each domain independently. Amide RDCs measured in FusB bound to EF-GC3 produced a good 
fit for both the N- and C-terminal domains of the FusB crystal structure15 (Supplementary Fig. 3), showing that 
neither domain undergoes significant internal structural changes upon binding to EF-GC3. RDC measurements 
on domain V of EF-GC3 bound to FusB also produced a good fit to the EF-G crystal structure17, indicating no 
substantial conformational changes occur within this domain upon complexation. RDCs for domain IV fit well to 
most of the domain, but poor fits for the first α -helix and part of the second suggest that the orientations of these 
helices change upon binding of FusB (Supplementary Fig. 4). Structural changes within domain III could not be 
assessed due to resonance broadening upon binding to FusB (see below). To model the structural changes within 
domain IV upon complexation, the crystal structure of the domain, excluding these α -helices, was fixed and the 
helices refined in orientation against the RDCs as rigid bodies hinged within flexible loops using Xplor-NIH34. 
Solvent PREs, in which a paramagnetic species is introduced into the bulk solvent to measure the degree of sol-
vent exposure of residues within a protein26, were measured in EF-GC3 bound to FusB and utilized as restraints 
in these calculations29. The inclusion of these restraints assisted in determining structural rearrangements and 
maintenance of a compact structure, resulting in a refined structural model of domain IV with a good fit to all 
secondary structure RDCs (Supplementary Fig. 4). To assess the quality of the fit to the RDCs, a Qfree was calcu-
lated using eight repeats and a random selection of 10% values in the free set. Refinement of the helices in domain 
IV reduced the Qfree from 0.53 to 0.42, confirming that the refinement improves the fit to the RDCs.
Step 2: Determining domain orientations in the complex using RDCs and solvent PREs. To determine whether the 
relative domain orientations in each protein were altered upon complexation, the previous independent fits of 
amide RDCs within secondary structure elements to each domain were compared to the fit for the whole of FusB 
and EF-GC3. The fit to the RDCs for both FusB and EF-GC3 was poorer than that achieved taking each domain 
separately, with higher Q factors than the independent fits (Supplementary Figs 3 and 4); furthermore, these 
separate fits produced different orientations for the alignment tensors of each domain, indicating a change in 
relative domain orientation on complexation. To characterize this domain reorientation, the individual domains 
(treated as rigid bodies hinged at the domain boundaries) were refined in orientation against the RDCs during 
restrained molecular dynamics simulated annealing calculations using Xplor-NIH34. In the case of EF-GC3, these 
calculations included restraints produced by solvent PREs. As a result of broadening of signals within domain III 
of EF-GC3 upon complexation, no restraints could be determined for this domain; this domain was therefore left 
unrestrained during structure calculations to avoid biasing the structural model. Structure calculations suggested 
a modest reorientation of the N-terminal domain of FusB relative to the C-terminal domain, which gave a better 
fit to the RDCs (Q factor of 0.40, compared with 0.59 for the apo crystal structure). The Qfree, calculated as above, 
reduced from 0.61 to 0.55 upon refinement, confirming the improvement in the fit to the RDCs. The refined, 
FusB-bound structure of EF-GC3 produced by these calculations exhibited a better fit to the RDCs than the apo 
crystal structure (Supplementary Fig. 4) (Q factor of 0.21, compared with 0.43 for the apo crystal structure). The 
Qfree, calculated as above, reduced from 0.48 to 0.39 during refinement, validating the fit to the reoriented con-
formation. This refinement step therefore produced models of the domain orientations in both proteins in the 
complex that agreed well with experimental restraints.
Step 3: Docking of the individual refined protein structures to produce a structural model of the complex. To com-
plete the structural model of the FusB•EF-GC3 complex, we considered together chemical shift perturbation 
(CSP) data identifying the primary binding sites, RDC data to restrain the relative orientations of the two pro-
teins and PRE data within EF-GC3 bound to FusB MTSL tagged at residues 19, 26 and 150 (as detailed in materials 
and methods and supplementary information) for residues showing an Iox/Ired (the ratio of peak intensity in the 
MTSL tagged and diamagnetic samples) greater than 0.9 or less than 0.1 (yielding long range distance restraints). 
These data were used to drive semi-rigid docking of the two proteins in the conformations determined above 
using HADDOCK35. Docking calculations produced a unique solution with an average RMSD of 0.68 Å over 200 
structures that was consistent with all of our data. The use of only PREs with Iox/Ired > 0.9 or < 0.1 in docking cal-
culations allowed the remaining, intermediate PREs to be used to verify the model by comparison with calculated 
values. Theoretical PREs calculated from the final model were therefore compared to experimental values for all 
residues, including those omitted from the docking calculation, to confirm the structural model was consistent 
with PRE data (Supplementary Fig. 5).
A structural model of the FusB•EF-GC3 complex. Utilizing the approach outlined above, we produced 
an unambiguous structural model of the FusB•EF-GC3 complex. This model reveals that both FusB and EF-GC3 
undergo interdomain reorientation upon complexation, with EF-GC3 also undergoing intradomain rearrange-
ment within the vicinity of the FusB binding site, as detailed below.
CSP analysis established that the primary FusB binding site forms a patch on one face of domain IV of EF-GC3 
that centers on β -strand IVIII (Fig. 2a–c). The corresponding binding site for EF-GC3 on FusB was previously 
mapped to the C-terminal domain of the latter;14 here, this binding site was more precisely delineated (Fig. 2), 
revealing that the interaction interface involves the second β -sheet and last α -helix of the C-terminal domain 
of FusB, fully encompassing the zinc coordination site, and extending to the boundary between the N- and 
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Figure 2. Identification of residues that form the binding interface in EF-GC3 and FusB, and mapping of these 
binding sites onto the corresponding protein structures. (a) Combined 1H and 15N chemical shift changes in 
EF-GC3 upon binding FusB calculated only for those residues assigned in both apo and FusB bound spectra. CSPs 
considered significant (> 1.0 ppm) are shown in red. Residues for which peaks disappear from the spectrum upon 
complexation are shown as yellow circles. (N = 155) (b,c) Residues showing significant CSPs are indicated in red on 
180° rotated views of the crystal structure of apo EF-GC3 displayed as a ribbon diagram (b) and in surface view  
(c). Significant perturbations predominantly form a patch on one side of domain IV, and represent the primary site of 
interaction with FusB. (N = 167) (d) Combined 1H and 15N chemical shift changes in FusB upon binding to EF-GC3 
using direct measurement for residues assigned in both spectra and minimal shift changes for all residues assigned 
only in the apo spectrum assuming the closest bound state peak represents the same residue. CSPs considered 
significant (> 0.6 ppm) are shown in red. (e,f) Residues showing significant CSPs are indicated in red on the crystal 
structure of apo FusB as a ribbon diagram (e) and in surface view (f). Significant perturbations predominantly form a 
patch on one side of the C-terminal domain, and represent the primary site of binding to EF-G.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:19524 | DOI: 10.1038/srep19524
C-terminal domains (Fig. 2d–f). Additional, smaller and less well-defined regions of CSPs were observed on the 
β -sheet of domain V of EF-GC3 (Fig. 2a–c) and in the N-terminal domain of FusB, suggesting a secondary site of 
interaction between EF-GC3 and FusB (see below).
Refinement of the FusB and EF-GC3 crystal structures to RDC data in the complex revealed that both proteins 
undergo domain reorientation upon complexation. The N-terminal domain of FusB reorients by 9° relative to 
the C-terminal domain, although the internal structure of each domain remains unaltered. Domain V of EF-GC3 
undergoes a 21° reorientation with respect to domain IV upon complexation (Fig. 3). There is also some rear-
rangement of the internal structure of domain IV of EF-GC3 upon complexation; helix IVI becomes tilted upon 
FusB binding, with the C-terminal end of the helix moving away from the FusB binding site and towards the 
second helix, whilst helix IVII tilts away at the N-terminal end to compensate for this movement (Fig. 3).
Docking calculations identified a structure in which EF-GC3 and FusB interact via two binding sites; the 
C-terminal domain of FusB binds the β -sheet of EF-GC3 domain IV, and the N-terminal domain of FusB interacts 
with the β -sheet of EF-GC3 domain V (Fig. 4). The domain reorientations within both FusB and EF-GC3 result in 
sufficient movement of the N-terminal domain of FusB and domain V of EF-GC3 relative to the primary binding 
sites to allow the domains to interact while avoiding the steric clashes that occur between the apo structures when 
docked in this orientation. The structure of the complex places in close proximity the residues in domain V of 
EF-GC3 and the N-terminal domain of FusB that show otherwise unexplained CSPs; since these CSPs were not 
included in the docking parameters, this provides additional corroborating evidence for the validity of the struc-
ture. The structure of FusB•EF-GC3 we present here is consistent with all available data (Fig. 4), including that not 
used to inform calculation of the structure14,15,23, and reveals clearly how FusB and EF-G interact.
Binding of FusB alters the conformational flexibility of domain III in EF-G. A considerable num-
ber of the resonances visible in the 15N-TROSY-HSQC of apo EF-GC3 were lost upon complexation with FusB, 
without the concomitant emergence of new peaks (Fig. 5). In all, the latter spectrum lacked ~35% of the expected 
peaks from throughout EF-GC3, most of which represent signals from domain III. Whilst 75% of the potentially 
assignable residues in domain III could be successfully assigned in apo EF-GC3, only 14% were identified in 
the complex spectrum (Supplementary Fig. 6), indicating that most domain III resonances became broadened 
in the complex. This loss of domain III resonances from the spectrum could not be attributed to the overall 
broadening of resonances that occurs due to the increase in molecular size; we saw no similar loss of resonances 
from domains IV and V, both of which gave comparable peak intensities to domain III in the apo state. These 
data therefore indicate that binding of FusB to EF-GC3 prompts domain III to undergo conformational exchange 
with dynamic motions on a μ s-ms timescale. The fact that signals from throughout domain III are lost upon 
complexation, while those from the remainder of EF-GC3 are retained, suggests that the observed effect involves 
rearrangements throughout the domain rather than movement of the domain as a rigid body. Since domain III 
borders the site at which EF-G was truncated to yield EF-GC3, we sought confirmation that the observed effect 
was not an artefact of the truncated protein; amide spectra from full-length EF-G confirmed that this was not 
the case, with domain III signals also becoming lost from EF-G upon complexation with FusB (Supplementary 
Fig. 1). Although signals from domains I and II were not assigned in spectra of full length EF-G, these domains 
contributed approximately the expected number of peaks to spectra measured in both the apo and FusB-bound 
states, suggesting that the FusB-induced dynamics observed are limited to domain III. Furthermore, very few 
chemical shift changes were observed in resonances from domains I and II, and of those that were, all fell below 
the level considered significant in EF-GC3 upon FusB binding. Therefore, no significant conformational change 
appears to occur in domains I and II upon FusB binding.
Figure 3. Conformational change occurring in FusB and EF-GC3 upon complexation. The crystal structures 
of the apo states are shown in red, with the states present in the complex shown in blue. (a) Conformational 
change in FusB upon binding to EF-GC3 (structures aligned via the C-terminal domains). (b) Conformational 
change in domain IV of EF-GC3 upon binding to FusB (structures aligned via the domain IV β -sheet).  
(c) Conformational change in domain IV–V orientation in EF-GC3 upon binding to FusB (structures aligned 
via domain IV). The position of domain III in the FusB bound state of EF-GC3 is modelled on the position in the 
apo state crystal structure, since signal broadening resulted in a lack of data to restrain this domain (see text).
www.nature.com/scientificreports/
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To explore the conformational flexibility associated with domain III of EF-GC3 and to investigate whether 
FusB is likely to enhance the intrinsic dynamic properties of domain III or induce additional dynamics in the 
complex, we performed molecular dynamics simulations using GROMACS36. These simulations suggest that 
domain III of EF-G is more dynamic than domains IV and V (Fig. 5), with the first helix of the domain showing 
the greatest per residue RMSF throughout the simulation, a movement consistent with the broadening of res-
onances observed throughout domain III on FusB binding. Analysis of the distances between centers of mass 
for each domain throughout the simulations also indicates that domain III moves relative to domains IV and V. 
Principle component analysis of simulations suggest that domain III is capable of a range of motions, including 
a flexing of the domain and rotations relative to domains IV and V (Fig. 5). In addition, although domain III is 
largely ordered in the crystal structure of S. aureus EF-G17 and RDC data support its ordered conformation in 
the apo state in solution, several of the crystal structures of T. thermophilus EF-G show domain III to be partially 
disordered with areas of missing electron density18,20,37, further supporting the idea that this domain is capable of 
dynamic motion. FusB is therefore likely to enhance the intrinsic dynamic properties of domain III.
Figure 4. Structural model of the FusB•EF-GC3 complex. (a) The complex of FusB (green) bound to EF-GC3 
(blue), determined by docking the crystal structures of the proteins informed by NMR CSPs, RDCs and PREs. 
Residues showing significant CSPs are shown as red sticks. The position of domain III of EF-GC3 is taken from 
the 2XEX crystal structure as signal broadening meant that no data to restrain the position of this domain could 
be obtained. (b) The correlation between amide RDC measurements in secondary structure regions of EF-
GC3 bound to FusB and those calculated from the complex structure (N = 52). (c) Correlation between amide 
1H PREs measured in EF-GC3 bound to FusB-R19C-MTSL (red bars) and those calculated from the complex 
structure (blue line) (N = 123). (d,e) PREs to FusB-R19C-MTSL (FusB shown as a cartoon, R19 as magenta 
sticks) in EF-GC3, shown as a cartoon in (d) and a surface representation in (e). Residues with Iox/Ired > 0.9 are 
shown in blue, 0.7–0.89 in cyan, 0.5–0.69 in green, 0.3–0.49 in yellow, 0.1–0.29 in orange and < 0.1 in red. 
Residues for which there was no PRE data are shown in grey.
www.nature.com/scientificreports/
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Collectively, our results establish how FusB interacts with EF-G, and show that this interaction prompts con-
formational rearrangement in the latter, along with changes in the conformational flexibility of domain III. As 
discussed below, the ability of FusB to modulate the conformational properties of EF-G can explain the ability of 
FusB to drive release of EF-G from the ribosome, both in the presence and absence of FA.
Discussion
With the aid of a new NMR protocol for the structural characterization of large multidomain protein complexes, 
we have determined the architecture of the ~60 kDa complex formed between an antibiotic resistance protein 
(FusB) and a truncated form of the drug target it acts to protect (EF-G). This protein-protein interaction involves 
two regions of contact between the binding partners, with the C- and N-terminal domains of FusB interacting 
with domains IV and V of EF-G, respectively (Fig. 4). The structure of the FusB•EF-G complex differs substan-
tially from that previously modelled using unrestrained in silico docking14, in which FusB-type proteins were 
proposed to make contact with EF-G exclusively through their C-terminal domain, and adopt a binding orien-
tation ~180 degrees from that presented here. Determination of the structural basis for the interaction between 
these proteins now provides a solid foundation for understanding the mechanism of FusB-type resistance to FA.
In our earlier study, we considered it unlikely that FusB-type proteins bring about FA resistance by interfer-
ing with binding of the drug to EF-G14. This idea was based on (i) the observation that FusB is able to accelerate 
release of EF-G from the ribosome both in the presence and absence of FA, making it unnecessary to invoke a 
direct effect of the protein on drug binding to explain resistance, and (ii) the aforementioned in silico docking 
model of the two proteins, which suggested that FusB-type proteins bind at a site on EF-G removed from the FA 
binding site. The structural model presented here underscores this idea, confirming that the binding sites of FusB 
and FA are distinct and non-overlapping, and indeed that they involve different domains of EF-G (whilst FusB 
binds domains IV and V, FA recognizes a site between domains II and III21). In line with this, the closest approach 
that FusB makes to the FA binding site in the structure of the complex presented here is 17 Å distant.
We also speculated previously that FusB-type proteins might drive dissociation of EF-G from the ribosome by 
directly competing with the latter for EF-G binding, an idea again based on the earlier in silico docking studies, 
which implied that binding of EF-G to the ribosome and FusB represent mutually exclusive events14, and on the 
Figure 5. Domain III of EF-GC3 undergoes dynamic changes upon binding to FusB. (a) Overlay of the 
15N-TROSY-HSQC of apo EF-GC3 (blue) and EF-GC3 bound to FusB (red). Peaks from domain III are identified 
by underlined labels and are absent from the spectrum determined in the presence of FusB. (b) Backbone 
RMSF per residue determined from molecular dynamics simulations of EF-GC3. Domain III shows greater 
dynamic motions than domains IV and V, particularly within the first helix and β -strand. (c) Probability density 
functions for distance distributions between the centres of mass for domains III-IV and IV–V showing greater 
variation in the distances for domains III–IV, suggesting domain III is flexible. (d) The extent of motions of 
domain III relative to domains IV and V identified by molecular dynamics simulations. Structures are aligned 
on both domains IV and V, and residues in regions linking the three domains were ommited from the analysis.
www.nature.com/scientificreports/
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high affinity of FusB-type proteins for EF-G14. Examination of the FusB•EF-GC3 complex structure determined 
in this study, in conjunction with published structures of EF-G bound to the ribosome21,38, indicates that the 
FusB binding site on EF-G would likely be fully accessible even when the latter is bound to the ribosome (Fig. 6). 
Consequently, our present study finds no evidence in support of the idea that FusB might drive release of EF-G 
by direct competition with the ribosome.
Instead, our findings point to FusB-induced conformational change and dynamics in EF-G as the basis for 
its biological mechanism. We have identified two types of effect occurring in EF-G upon complexation with 
FusB; alterations in inter- and intra-domain conformation at the C-terminus of the protein, and a change in 
the conformational flexibility of domain III. The latter effect may represent a direct consequence of the former, 
with FusB-induced conformational change in domains IV and V acting to disrupt the interfaces between these 
domains and domain III, thereby releasing this intrinsically dynamic domain from restraint. Conformational 
change is central to the function of EF-G; comparison of structures of this protein determined in the apo form17,18, 
Figure 6. Structure of the FusB•EF-G complex, and the mechanism of FA resistance. (a) A model of FusB 
binding to full length EF-G produced by aligning the FusB•EF-GC3 structural model with the crystal structure 
of ribosome bound EF-G. EF-G is colored by domain and FusB is shown in cyan. (b) The model of the FusB•EF-
GC3 complex docked (by sequence alignment of domains IV and V) onto EF-G bound to the ribosome in the 
post-translocational state. EF-GC3 is shown in blue, FusB in green, EF-G bound to the ribosome in red, and 
the ribosome in grey. (c) Suggested mechanism of FusB-mediated resistance to FA. EF-G (brown) binds to the 
ribosome (blue and white) after peptide bond formation between the A and P site amino acids and mediates 
translocation to the P and E sites. EF-G then dissociates making the A site available for binding of the next 
tRNA. In the presence of the drug, FA (yellow) binds to EF-G on the ribosome in the post-translocation state (1) 
and stalls protein synthesis by preventing EF-G release. Binding of FusB (purple) to EF-G in stalled complexes 
(2) induces a conformational change in domains IV and V of EF-G and a change in the dynamics of domain III 
(3). Either this conformational change is sufficient to promote release of EF-G or the dynamics within domain 
III allow the C-terminal domains of EF-G to more readily adopt the conformation relative to domains I and II 
required for release, without the requirement for transmission of conformational change from domains I and II. 
This results in dissociation of EF-G from the ribosome, thereby allowing protein synthesis to continue (4).
www.nature.com/scientificreports/
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nucleotide-bound form19,20, and resident on the ribosome pre- and post-translocation21,22,38, show that EF-G 
undergoes major structural rearrangements throughout the translocation cycle, most of which involve domains 
I and II moving relative to domains III-V39. For EF-G to dissociate from the ribosome once translocation has 
occurred, conformational change upon GTP hydrolysis is transmitted from domains I and II to domain IV to 
disrupt the contacts that this latter domain makes with the 30S subunit of the ribosome22. Dissociation of EF-G 
from the ribosome is inhibited by FA, which binds to EF-G between domains II and III, and apparently restricts 
this transmission of conformational change21. FusB-induced conformational change in domains IV-V of EF-G 
and altered dynamics in domain III presumably predispose EF-G to release from the ribosome, and thereby act to 
accelerate dissociation of EF-G from the ribosome in both the absence and presence of FA.
How does FusB-induced conformational change in EF-G facilitate release of the latter from the ribosome? 
One possibility is that the minor structural rearrangements occurring in domains IV and V of EF-G upon com-
plexation with FusB directly impact the interaction of the protein with the ribosome, and are alone sufficient to 
favor dissociation. Alternatively, FusB may drive release of EF-G from the ribosome as a consequence of alloster-
ically triggering dynamic motion in domain III. Domain III acts as a central hub to relay conformational change 
between domains I-II and IV-V of the protein21,39–42, and therefore plays a crucial role in the transmission of 
structural rearrangement effecting dissociation of EF-G from the ribosome. By prompting changes in the dynam-
ics of domain III, FusB might allow the C-terminal domains of EF-G to more readily adopt the conformation rel-
ative to domains I and II required for release, without the requirement for transmission of conformational change 
from domains I and II (Fig. 6). Future studies will focus on distinguishing these two possibilities.
Material and Methods
Additional details are available in SI Materials and Methods.
Protein expression and purification. FusB, EF-G and EF-GC3 were expressed and purified as previously 
described14. FusB and EF-GC3 were both produced with either 15N, 13C and partial 2H labelling, 15N, partial 2H 
labelling or no specific labelling while EF-G was produced with ILVA methyl 13C, 1H labelling on a uniformly 
12C, 2H background, as detailed in supplementary materials and methods. Selective amino acid unlabelling was 
achieved by adding 1g/l of a single amino acid to 15N 2H autoinduction medium as described43.
NMR Spectroscopy. NMR experiments were performed at 25 °C on either an Agilent Inova 600 MHz spec-
trometer with a room temperature probe, a Varian Inova 750 MHz spectrometer with a cryogenic probe or a 
Varian Inova 900 MHz spectrometer with a cryogenic probe (UK Biomolecular NMR facility, Birmingham). 
Samples for backbone assignment were produced using 0.3 mM 15N, 13C partially-deuterated EF-GC3 whilst sam-
ples for RDC and PRE measurements were produced using 0.3 mM 15N partially-deuterated FusB or EF-GC3. 
Samples of full length EF-G were prepared using 50 μ M 15N perdeuterated EF-G with 13C-1H labelled methyl 
groups of alanine, leucine, valine and isoleucine. For studies of either protein in the complex the labelled protein 
was saturated with 1.5× the concentration of the non-isotopically enriched binding partner. All experiments 
were performed using TROSY modifications44, and deuterium decoupling where required. Data were processed 
in NMRPipe45 before assignment and measurement of CSPs using CCPN analysis46. Peak intensity measurements 
for calculation of ARTSY-based RDCs, PREs and solvent PREs were made using NMRView47.
Backbone assignment. Backbone assignments of EF-GC3 in the apo and complex state were determined from 
analysis of HNCA, HNCO, HN(CO)CA, HN(CA)CO, HNCACB and HN(CO)CACB spectra with TROSY 
modifications. These assignment spectra were supplemented using selectively unlabelled43 samples in which 15N 
EF-GC3 was enriched with a single non-isotopically enhanced amino acid (alanine, asparagine, lysine, valine and 
phenylalanine). Assignments of FusB bound to EF-GC3 were transferred from the apo spectra by visual inspection 
with the use of a series of spectra of single amino acid selectively unlabelled lysine, leucine, phenylalanine, valine 
and asparagine 15N FusB bound to EF-GC343.
Chemical shift perturbation analysis. 1H-15N chemical shift perturbation analysis was performed using 
direct calculation for residues assigned in both spectra and then using conservative chemical shift 
perturbation analysis for all other residues, finding the closest peak in unassigned spectrum to the 
assigned peaks in the apo spectrum48. The chemical shift change was calculated using the metric 
∆ = (δ ) + ( × δ )/ /
.[ N 5 N ]15 apo complex
2 1
apo complex
2 0 548. A cut-off for chemical shift changes of 1.0 ppm was 
applied for differences between EF-GC3 in the apo and FusB bound states, 0.6 ppm for differences between 
FusB in the apo and EF-GC3 bound states and 0.4 ppm for differences between EF-GC3 and EF-G. The cut-off 
for FusB was chosen to be consistent with previously published data14 while the remaining cut-offs were chosen 
to class any change greater than 1 standard deviation above the mean chemical shift difference as significant.
Amide RDC measurements. Amide RDC measurements in apo FusB and EF-GC3 were measured using 15N 
labelled partially deuterated protein in 5% polyacrylamide gels compressed to ⅔ original height by a Shigemi tube 
plunger. RDCs were quantified from the difference in position between peaks in TROSY and 15N semi-TROSY 
spectra. RDCs for FusB and EF-GC3 in the complex were measured using two protein samples: (i) 15N, partially 
2H labelled EF-GC3 in complex with unlabelled FusB and (ii) 15N, partially 2H labelled FusB in complex with unla-
belled EF-GC3. Each sample was aligned in 6 mg/ml Pf1 phage and RDCs recorded using the 2D ARTSY pulse 
sequence49. 71 and 41 15N, 1H RDCs in the range –28.5 to + 19.4 Hz were obtained for EF-GC3 and FusB samples 
respectively using only residues within secondary structure elements. Data were fitted to the crystal structures 
using PALES50 and the quality of the fit assessed through the Q factor and correlation coefficients resulting from 
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this fit. Qfree values were calculated by omitting 10% RDCs (the free set) from the calculation, and then comparing 
the free set RDCs with values back-calculated from the refined model. The Qfree calculations were repeated eight 
times, and an average Qfree was calculated over all repeats.
PRE measurements. For PRE measurements, pET-28a: fusB14 was modified to encode FusB independently har-
boring amino acid substitutions R19C and T26C in the N-terminal domain, and N150C in the C-terminal domain 
(Genscript) which were labelled using MTSL as described in supplementary materials and methods. Each substi-
tution was at a solvent exposed, non-conserved residue. 15N-TROSY-HSQC spectra of the mutant proteins estab-
lished that these amino acid substitutions did not perturb the structure of FusB, except in the immediate vicinity 
of the substitution (Supplementary Fig. 7). Amide 1H PRE effects were made from the ratio of peak intensities 
from 15N-TROSY-HSQC spectra measured from 15N, partially deuterated EF-GC3 bound to MTSL tagged FusB 
mutants and 15N, partially deuterated EF-GC3 bound to untagged FusB as sample degradation prevented the use 
of reduced MTSL tagged samples.
Solvent PREs. Solvent PREs from amide proton R1 relaxation measurements were measured for 15N deuterated 
EF-GC3 bound to non-isotopically enriched FusB using 0.0, 0.25, 0.5, 0.75 and 1.0 mM Gd-DPTA-BMA as the 
probe and following the method of Madl et. al.26, as detailed in supplementary materials and methods.
Structure calculation. Modelling of conformational changes. To model conformational changes upon com-
plexation, the crystal structures were refined to better fit the RDC and solvent PRE data using Xplor-NIH34 and 
the method of Wang et. al.29. For refinement of the EF-GC3 domain IV internal conformation, the structure of all 
three domains excepting the domain IV helices and the loops joining them to the remainder of the structure was 
fixed while the helices were allowed to move as a rigid body. For realignment of domains IV and V of EF-GC3, 
domain IV was fixed while domain V was allowed to move as a rigid body with restraints included from RDCs 
from both domains. Domain III was allowed to move unrestrained as a rigid body to prevent it from sterically 
hindering domain realignment. To maintain a compact protein structure, solvent PRE restraints were included in 
all EF-GC3 calculations using the method of Wang et. al.29. Calculation of an ensemble of 100 structures converged 
well with this model with an average RMSD from the lowest energy structure for Cα atoms of 0.38 Å for the best 
50 structures. For realignment of the two domains of FusB, the C-terminal domain was fixed and the N-terminal 
domain allowed to move as a rigid body. Calculation of an ensemble of 100 structures converged well with this 
model with an average RMSD from the lowest energy structure for Cα atoms of 0.08 Å for the best 50 structures.
Docking calculations. Docking of the structure of EF-GC3 with realigned domains IV and V and that of FusB 
with realigned domains was performed using HADDOCK35. Interaction surfaces were defined by ambiguous 
interaction restraints (AIRs) determined from those residues showing significant chemical shift perturbation on 
binding that were solvent exposed in the crystal structures. Orientational information for the two proteins was 
provided by the inclusion of RDCs from EF-GC3 domains IV and V and full length FusB. To compensate for dif-
ferences in the degree of alignment between samples, the RDCs from EF-GC3 were scaled by a factor of 2.4. NOE 
style distance restraints were included using intermolecular PRE data, with residues showing an Iox/Ired greater 
than 0.9 defined as 25 Å or greater from the MTSL tag. Residues with an Iox/Ired less than 0.1 were defined as 15 
Å or less from the MTSL tag. PREs with intermediate values (Iox/Ired > 0.1 and Iox/Ired < 0.9) were not included in 
the docking calculation, but were subsequently compared to values calculated from the docked model to verify 
the quality of the complex structure. The numbers of each distance restraint included in structure refinement and 
docking are shown in supplementary Table 1. Theoretical PREs from the final model were then compared to all 
experimental values to further validate the structural model.
All figures of protein structures were produced using the PyMOL Molecular Graphics System, Version 1.1, 
Schrodinger, LLC.
Molecular dynamics simulations. All MD simulations were performed using GROMACS (version 4.6.5)36 
using EF-G (PDB code 2XEX) as a starting point for the simulations. Domains III to V (residues 401 to 693) were 
taken from the structure by removing the rest of the protein, and missing residues 442–444 were rebuilt using 
Xplor-NIH34. The starting structure was solvated using the SPC water model; the thickness of the explicit water 
layer was at least 1.0 nm from the protein molecule. The systems were neutralized with Na+ and Cl− ions and 
were equilibrated before and after insertion of ions. Production simulations were performed at constant temper-
ature, pressure and number of particles. The all-hydrogen force field CHARMM27 was used for the simulations. 
Temperature and pressure were controlled using Berendsen weak coupling. All bonds with hydrogen atoms were 
constrained by the LINCS algorithm. Coulomb interactions were computed with the PME method. 10 Å cut-offs 
were used for the electrostatic and van der Waals interactions; a neighbor list for non-bonded interactions was 
included based on a cut-off of 10 Å. The simulation was run for 100 ns; the last 90 ns were taken for the analysis; 
the analysis was performed using standard procedures (g_rms, g_dist, g_covar, g_anaeig) from the GROMACS 
package.
Data deposition. NMR chemical shift assignments for apo EF-GC3 have been deposited in the BMRB (entry 
number 25368), as have assignments and structural restraints for the FusB•EF-GC3 complex (entry number 
25504). The structural model of the FusB•EF-G complex has been deposited in the PDB (PDB ID 2MZW).
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